281 related articles for article (PubMed ID: 26946161)
1. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
2. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
3. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
4. Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.
Al Hussein Al Awamlh B; Wu X; Barocas DA; Moses KA; Hoffman RM; Basourakos SP; Lewicki P; Smelser WW; Arenas-Gallo C; Shoag JE
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):395-402. PubMed ID: 35882950
[TBL] [Abstract][Full Text] [Related]
5. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
7. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
9. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
10. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
11. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
12. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
14. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
17. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
[TBL] [Abstract][Full Text] [Related]
18. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
19. Population-based assessment of determining predictors for quality of prostate cancer surveillance.
Chamie K; Williams SB; Hershman DL; Wright JD; Nguyen PL; Hu JC
Cancer; 2015 Dec; 121(23):4150-7. PubMed ID: 26307939
[TBL] [Abstract][Full Text] [Related]
20. Racial Disparities in Active Surveillance for Prostate Cancer.
Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]